Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1041
Primary information
GENENEU4
NUMBER OF ASSAY217
ASSAY IDs147478 147477 147476 427116 427114 427115 427117 427113 203526 203525 203520 203519 203531 203529 203528 203371 203357 313830 313828 313829 704187 532122 532120 532112 532108 532106 427111 532121 532107 427118 427109 532113 203527 228430 93046 644394 644393 203374 203363 532115 532114 1308296 1308294 1308295 313831 1308298 1308297 368578 473065 306105 294224 203672 203544 203541 203540 203530 1160997 203373 761715 704188 634128 634127 591599 532123 532109 466940 466937 203380 203546 203545 203537 203532 147316 1308329 1308328 1308327 1308326 1308325 1308324 1308323 1308322 1308321 1308320 1308319 1308318 1308317 1308316 1308315 1308314 1308313 1308312 1308311 1308310 1308309 1308308 1308307 1308306 1308305 1308304 1308303 1308302 1308301 1308300 1308299 466938 203517 644398 644395 644400 532116 368579 368571 343957 293514 203673 203670 203542 203538 203523 203521 2035
Assay Name1. In vitro inhibitory activity against B/Lee/40 Influenza B Neuraminidase.,2. In vitro inhibitory activity against B/Lee/40 Influenza B Neuraminidase.,3. In vitro inhibitory activity against H1N9 Influenza A Neuraminidase.,4. Inhibition of human NEU3 transiently transfected in HEK293T cells by fluorimetric high-performance liquid chromatography,5. Inhibition of human NEU1 transiently transfected in HEK293T cells by fluorimetric analysis,6. Inhibition of human NEU2 transiently transfected in HEK293T cells by fluorimetric analysis,7. Inhibition of human NEU4 transiently transfected in HEK293T cells by fluorimetric analysis,8. Inhibition of human NEU4 transiently transfected in HEK293 cells by fluorimetric analysis,9. The compound was tested in vitro for the inhibitory concentration against influenza B/Mem/89 sialidase from whole virus by fetuin assay,10. The compound was tested in vitro for the inhibitory concentration against influenza B/Mem/89 sialidase from whole virus by MUN assay,11. The compound was tested in vitro for the inhibitory concentration against influenza N2 sialidase from whole virus by fetuin assay,12. The compound was tested in vitro for the inhibitory concentration against influenza N2 sialidase from whole virus by MUN assay,13. Compound was tested for inhibitory concentration against Influenza sialidase type A,14. Compound was tested for inhibitory concentration against Influenza sialidase type B,15. Compound was tested for inhibitory concentration against Influenza sialidase type A,16. Compound was tested for inhibitory concentration against Influenza sialidase type B,17. Compound was tested for inhibitory concentration against Influenza sialidase type A,18. Inhibition of human NEU3 expressed in HEK293 cells,19. Inhibition of human NEU1 expressed in HEK293 cells,20. Inhibition of human NEU2 expressed in HEK293 cells,21. Inhibition of Influenza A virus sialidase N2,22. Activity of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography,23. Activity of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography,24. Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate,25. Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate,26. Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate,27. Inhibition of human NEU3 transiently transfected in HEK293 cells by fluorimetric analysis,28. Activity of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography,29. Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate,30. Inhibition of human NEU2 transiently transfected in HEK293 cells by Line-Weaver Burk plotting,31. Inhibition of human NEU2 transiently transfected in HEK293 cells by fluorimetric analysis,32. Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate,33. Compound was tested for the inhibition of influenza virus sialidase using 2'-(4-methylumbelliferyl)-N-acetylneuraminic acid substrate,34. Km value for transferase activity of Trypanosoma cruzi trans-sialidase,35. Km value for hydrolase activity of Trypanosoma cruzi trans-sialidase,36. Competitive inhibition of Clostridium perfringens ATCC 10543 sialidase Nan1 c-terminal catalytic domain using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by Lineweaver-Burk and Dixon plot analysis,37. Inhibition of Clostridium perfringens ATCC 10543 sialidase Nan1 c-terminal catalytic domain using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by fluorimetric analysis,38. Inhibitory activity against sialidase of influenza B,39. Inhibitory activity against sialidase of influenza A,40. Inhibition of human influenza A virus A/Aichi/2/1968(H3N2) neuraminidase by fluorometric method using 4MU-NeuAc substrate,41. Inhibition of human Influenza A virus A/PR/8/34(H1N1) neuraminidase by fluorometric method using 4MU-NeuAc substrate,42. Inhibition of human Neu1 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis,43. Inhibition of human Neu3 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis,44. Inhibition of human Neu2 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis,45. Inhibition of human NEU4 expressed in HEK293 cells,46. Inhibition of human Neu4 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis,47. Inhibition of human Neu4 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis,48. Inhibition of Trypanosoma cruzi trans-Sialidase by MuNANA assay,49. Inhibition of human neuraminidase 2,50. Inhibition of sialidase in Human parainfluenza virus 3 C243,51. Inhibition of Trypanosoma cruzi trans-sialidase after 15 mins,52. Compound was tested for its inhibitory activity against sialidase (Flu B, 4 nM).,53. Compound was tested for its inhibitory activity against sialidase (influenza A virus by enzyme inhibition assay.).,54. Compound was tested for its inhibitory activity against sialidase (Flu B, 4 nM).,55. Inhibition of sialidase (Flu A, 5 nM),56. Compound was tested for its inhibitory activity against sialidase (Flu B, 4 nM).,57. Inhibition of recombinant Trypanosoma cruzi trans-sialidase catalytic N-terminal domain preincubated for 10 mins by continuous fluorimetric assay,58. Inhibitory activity against influenza B sialidase (Victoria),59. Inhibition of influenza A virus A/Paris/2590/2009 (pdm09 H1N1) N1 sialidase using fluorogenic substrate 4-methylumbelliferyl N-acetyl-alpha-D-neuraminide preincubated for 15 mins measured after 30 mins by spectrofluorometry,60. Inhibition of Influenza A virus sialidase N2 by fluorometric assay,61. Binding affinity to Trypanosoma cruzi trans-Sialidase by surface plasmon resonance assay,62. Inhibition of Trypanosoma cruzi trans-Sialidase,63. Inhibition of Human parainfluenza virus 1 sialidase using N-acetyl-alpha-neuramic acid by fluorometric assay,64. Activity of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography,65. Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate,66. Noncompetitive inhibition of Trypanosoma cruzi trans-sialidase containing catalytic domain (N58F, R200K) and lectin-like domain (S495 K, V496G, E520K, D593G, I597D, H599R) mutation expressed in Escherichia coli JM109 by discontinuous fluorimetric assay using Lineweaver-Burke plot,67. Inhibition of Trypanosoma cruzi trans-sialidase containing catalytic domain (N58F, R200K) and lectin-like domain (S495 K, V496G, E520K, D593G, I597D, H599R) mutation expressed in Escherichia coli JM109 assessed as MuNANA substrate hydrolysis in presence of 0.1% Triton X-100 by discontinuous fluorimetric assay,68. Inhibitory activity against influenza virus A(N9) sialidase,69. Compound was tested for its inhibitory activity against B/Lee/40 sialidases.,70. Compound was tested for its inhibitory activity against B/Beijing/1/87 (N2) sialidases.,71. Compound was tested for its inhibitory activity against A/Victoria/3/75 (N2) sialidases.,72. Compound was tested for its inhibitory activity against A/Aichi/2/68 (N2) sialidases.,73. The compound was tested for its inhibitory activity against bacterial neuraminidase,74. Antiviral activity against Influenza A virus (A/Aichi/75/2008(H3N2)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,75. Antiviral activity against Influenza A virus A/Kitakyushu/10/06(H1N1) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,76. Antiviral activity against Influenza A virus A/Yamaguchi/20/06(H1N1) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,77. Antiviral activity against Influenza A virus (A/Narita/1/2009(H1N1)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,78. Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,79. Antiviral activity against Influenza A virus A/duck/Tsukuba/441/05(H11N9) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,80. Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2006(H3N8)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,81. Antiviral activity against Influenza A virus (A/duck/Tsukuba/700/2007(H7N7)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay,82. Antiviral activity against Influenza A virus (A/duck/Shiga/8/2004(H4N6)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluor
ACTIVITYSubstance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 3 Active, 9 Tested Substance BioActivity: 5 Active, 1 Activity <= 1 µM, 9 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 2 Active, 13 Tested Substance BioActivity: 2 Active, 15 Tested Substance BioActivity: 2 Active, 14 Tested Substance BioActivity: 2 Active, 14 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 2 Active, 1 Activity <= 1 µM, 2 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 3 Active, 1 Activity <= 1 µM, 7 Tested Substance BioActivity: 6 Active, 5 Activity <= 1 µM, 7 Tested Substance BioActivity: 11 Tested Substance BioActivity: 3 Active, 11 Tested Substance BioActivity: 1 Active, 11 Tested Substance BioActivity: 6 Active, 1 Activity <= 1 nM, 5 Activity <= 1 µM, 6 T